AI platform that accelerates cell and gene therapy drug discovery through rational design of molecular constructs and vectors.
WhiteLab Genomics uses a proprietary AI-led framework combining advanced algorithms, curated databases, and computational biology to optimize therapeutic candidates for genomic medicine. The platform covers target receptor identification, viral vector design across AAV, lentivirus, and nanoparticle modalities, non-viral vector design, payload design, and bioproduction optimization. It is designed to accelerate and de-risk discovery for cell therapy, RNA therapy, and DNA therapy programs for biotech and pharma collaborators. Founded in 2019 and backed by Y Combinator. WhiteLab Genomics is a product of WhiteLab Genomics.